nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP2C19—coronary artery disease	0.109	0.643	CbGaD
Gefitinib—ALB—coronary artery disease	0.0607	0.357	CbGaD
Gefitinib—ORM1—Penbutolol—coronary artery disease	0.0297	0.0587	CbGbCtD
Gefitinib—ORM1—Pitavastatin—coronary artery disease	0.026	0.0513	CbGbCtD
Gefitinib—ABCG2—Pitavastatin—coronary artery disease	0.0159	0.0313	CbGbCtD
Gefitinib—ABCG2—Telmisartan—coronary artery disease	0.0159	0.0313	CbGbCtD
Gefitinib—ABCG2—Rosuvastatin—coronary artery disease	0.0117	0.0231	CbGbCtD
Gefitinib—ABCG2—Ezetimibe—coronary artery disease	0.0117	0.0231	CbGbCtD
Gefitinib—ALB—Pitavastatin—coronary artery disease	0.0109	0.0216	CbGbCtD
Gefitinib—ABCG2—Pravastatin—coronary artery disease	0.0106	0.021	CbGbCtD
Gefitinib—ALB—Valsartan—coronary artery disease	0.0106	0.021	CbGbCtD
Gefitinib—ABCB1—Ticagrelor—coronary artery disease	0.0106	0.0209	CbGbCtD
Gefitinib—CYP3A5—Clopidogrel—coronary artery disease	0.0101	0.0199	CbGbCtD
Gefitinib—CYP2C9—Fenofibrate—coronary artery disease	0.00973	0.0192	CbGbCtD
Gefitinib—CYP2C19—Gemfibrozil—coronary artery disease	0.00935	0.0185	CbGbCtD
Gefitinib—CYP3A5—Eplerenone—coronary artery disease	0.00935	0.0185	CbGbCtD
Gefitinib—CYP2C19—Clopidogrel—coronary artery disease	0.00811	0.016	CbGbCtD
Gefitinib—ALB—Rosuvastatin—coronary artery disease	0.00806	0.0159	CbGbCtD
Gefitinib—ALB—Acetylsalicylic acid—coronary artery disease	0.00785	0.0155	CbGbCtD
Gefitinib—CYP2C9—Gemfibrozil—coronary artery disease	0.00778	0.0154	CbGbCtD
Gefitinib—ALB—Captopril—coronary artery disease	0.00776	0.0153	CbGbCtD
Gefitinib—CYP2C19—Telmisartan—coronary artery disease	0.00709	0.014	CbGbCtD
Gefitinib—CYP2C9—Clopidogrel—coronary artery disease	0.00674	0.0133	CbGbCtD
Gefitinib—ABCB1—Clopidogrel—coronary artery disease	0.00654	0.0129	CbGbCtD
Gefitinib—ABCB1—Perindopril—coronary artery disease	0.00654	0.0129	CbGbCtD
Gefitinib—CYP3A5—Rosuvastatin—coronary artery disease	0.00648	0.0128	CbGbCtD
Gefitinib—CYP3A4—Ticagrelor—coronary artery disease	0.00635	0.0125	CbGbCtD
Gefitinib—ALB—Furosemide—coronary artery disease	0.00624	0.0123	CbGbCtD
Gefitinib—ALB—Losartan—coronary artery disease	0.00611	0.0121	CbGbCtD
Gefitinib—CYP3A5—Simvastatin—coronary artery disease	0.00602	0.0119	CbGbCtD
Gefitinib—CYP3A5—Lovastatin—coronary artery disease	0.00589	0.0116	CbGbCtD
Gefitinib—CYP3A5—Pravastatin—coronary artery disease	0.00589	0.0116	CbGbCtD
Gefitinib—CYP2C9—Pitavastatin—coronary artery disease	0.00589	0.0116	CbGbCtD
Gefitinib—CYP2C9—Valsartan—coronary artery disease	0.00573	0.0113	CbGbCtD
Gefitinib—ABCB1—Pitavastatin—coronary artery disease	0.00572	0.0113	CbGbCtD
Gefitinib—ABCB1—Telmisartan—coronary artery disease	0.00572	0.0113	CbGbCtD
Gefitinib—CYP2C19—Timolol—coronary artery disease	0.00571	0.0113	CbGbCtD
Gefitinib—CYP3A4—Fenofibrate—coronary artery disease	0.00566	0.0112	CbGbCtD
Gefitinib—ABCB1—Enalapril—coronary artery disease	0.00542	0.0107	CbGbCtD
Gefitinib—ABCB1—Lisinopril—coronary artery disease	0.00542	0.0107	CbGbCtD
Gefitinib—CYP3A5—Atorvastatin—coronary artery disease	0.00537	0.0106	CbGbCtD
Gefitinib—CYP2C19—Rosuvastatin—coronary artery disease	0.00523	0.0103	CbGbCtD
Gefitinib—CYP2C19—Acetylsalicylic acid—coronary artery disease	0.00509	0.0101	CbGbCtD
Gefitinib—CYP3A5—Losartan—coronary artery disease	0.00491	0.0097	CbGbCtD
Gefitinib—CYP2C19—Simvastatin—coronary artery disease	0.00486	0.00959	CbGbCtD
Gefitinib—CYP2C19—Lovastatin—coronary artery disease	0.00475	0.00939	CbGbCtD
Gefitinib—CYP2D6—Niacin—coronary artery disease	0.00467	0.00923	CbGbCtD
Gefitinib—ABCB1—Timolol—coronary artery disease	0.00461	0.0091	CbGbCtD
Gefitinib—CYP3A4—Gemfibrozil—coronary artery disease	0.00452	0.00893	CbGbCtD
Gefitinib—CYP2C9—Rosuvastatin—coronary artery disease	0.00434	0.00858	CbGbCtD
Gefitinib—CYP2D6—Timolol—coronary artery disease	0.00434	0.00858	CbGbCtD
Gefitinib—CYP2C19—Atorvastatin—coronary artery disease	0.00433	0.00855	CbGbCtD
Gefitinib—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.00423	0.00836	CbGbCtD
Gefitinib—ABCB1—Ezetimibe—coronary artery disease	0.00422	0.00833	CbGbCtD
Gefitinib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00411	0.00812	CbGbCtD
Gefitinib—CYP2C9—cardial valve—coronary artery disease	0.00409	0.13	CbGeAlD
Gefitinib—ABCB1—Captopril—coronary artery disease	0.00406	0.00802	CbGbCtD
Gefitinib—CYP2C9—Simvastatin—coronary artery disease	0.00404	0.00798	CbGbCtD
Gefitinib—CYP2C19—Losartan—coronary artery disease	0.00396	0.00782	CbGbCtD
Gefitinib—CYP2C9—Pravastatin—coronary artery disease	0.00395	0.00781	CbGbCtD
Gefitinib—CYP2C9—Lovastatin—coronary artery disease	0.00395	0.00781	CbGbCtD
Gefitinib—CYP3A4—Clopidogrel—coronary artery disease	0.00392	0.00774	CbGbCtD
Gefitinib—ABCB1—Simvastatin—coronary artery disease	0.00392	0.00774	CbGbCtD
Gefitinib—ABCB1—Pravastatin—coronary artery disease	0.00384	0.00758	CbGbCtD
Gefitinib—ABCB1—Lovastatin—coronary artery disease	0.00384	0.00758	CbGbCtD
Gefitinib—CYP2D6—Captopril—coronary artery disease	0.00382	0.00755	CbGbCtD
Gefitinib—CYP2D6—Simvastatin—coronary artery disease	0.00369	0.00729	CbGbCtD
Gefitinib—CYP3A4—Eplerenone—coronary artery disease	0.00364	0.0072	CbGbCtD
Gefitinib—CYP2D6—Lovastatin—coronary artery disease	0.00361	0.00714	CbGbCtD
Gefitinib—CYP2D6—Pravastatin—coronary artery disease	0.00361	0.00714	CbGbCtD
Gefitinib—CYP2C9—Atorvastatin—coronary artery disease	0.0036	0.00711	CbGbCtD
Gefitinib—ABCB1—Atorvastatin—coronary artery disease	0.00349	0.0069	CbGbCtD
Gefitinib—CYP2C9—Losartan—coronary artery disease	0.00329	0.0065	CbGbCtD
Gefitinib—CYP2D6—Atorvastatin—coronary artery disease	0.00329	0.0065	CbGbCtD
Gefitinib—CYP3A4—Enalapril—coronary artery disease	0.00325	0.00642	CbGbCtD
Gefitinib—ABCB1—Losartan—coronary artery disease	0.0032	0.00631	CbGbCtD
Gefitinib—Lapatinib—TAP1—coronary artery disease	0.00318	0.633	CrCbGaD
Gefitinib—CYP3A4—Ezetimibe—coronary artery disease	0.00253	0.00499	CbGbCtD
Gefitinib—CYP3A4—Rosuvastatin—coronary artery disease	0.00253	0.00499	CbGbCtD
Gefitinib—CYP3A4—Simvastatin—coronary artery disease	0.00235	0.00464	CbGbCtD
Gefitinib—CYP3A4—Lovastatin—coronary artery disease	0.0023	0.00454	CbGbCtD
Gefitinib—CYP3A4—Pravastatin—coronary artery disease	0.0023	0.00454	CbGbCtD
Gefitinib—CYP3A4—Atorvastatin—coronary artery disease	0.00209	0.00413	CbGbCtD
Gefitinib—CYP3A4—Losartan—coronary artery disease	0.00191	0.00378	CbGbCtD
Gefitinib—CSNK1E—cardiac ventricle—coronary artery disease	0.00116	0.037	CbGeAlD
Gefitinib—MKNK2—cardiac ventricle—coronary artery disease	0.00107	0.034	CbGeAlD
Gefitinib—IRAK1—cardiac ventricle—coronary artery disease	0.00107	0.034	CbGeAlD
Gefitinib—MKNK1—cardiac ventricle—coronary artery disease	0.00105	0.0335	CbGeAlD
Gefitinib—SBK1—blood—coronary artery disease	0.00103	0.0328	CbGeAlD
Gefitinib—MKNK2—myocardium—coronary artery disease	0.001	0.0319	CbGeAlD
Gefitinib—IRAK1—myocardium—coronary artery disease	0.001	0.0319	CbGeAlD
Gefitinib—MKNK1—myocardium—coronary artery disease	0.000991	0.0315	CbGeAlD
Gefitinib—CHEK2—blood—coronary artery disease	0.000899	0.0286	CbGeAlD
Gefitinib—EGFR—heart—coronary artery disease	0.000794	0.0253	CbGeAlD
Gefitinib—CSNK1E—heart—coronary artery disease	0.000763	0.0243	CbGeAlD
Gefitinib—IRAK4—heart—coronary artery disease	0.000752	0.0239	CbGeAlD
Gefitinib—ERBB3—heart—coronary artery disease	0.000737	0.0234	CbGeAlD
Gefitinib—MAP2K5—myocardium—coronary artery disease	0.000729	0.0232	CbGeAlD
Gefitinib—MKNK2—heart—coronary artery disease	0.0007	0.0223	CbGeAlD
Gefitinib—IRAK1—heart—coronary artery disease	0.0007	0.0223	CbGeAlD
Gefitinib—CHEK2—Pitavastatin—Rosuvastatin—coronary artery disease	0.0007	0.308	CbGdCrCtD
Gefitinib—ERBB3—Alprenolol—Penbutolol—coronary artery disease	0.000696	0.306	CbGdCrCtD
Gefitinib—MKNK1—heart—coronary artery disease	0.000692	0.022	CbGeAlD
Gefitinib—MKNK2—cardiovascular system—coronary artery disease	0.000661	0.021	CbGeAlD
Gefitinib—MKNK1—cardiovascular system—coronary artery disease	0.000653	0.0208	CbGeAlD
Gefitinib—MKNK2—cardiac atrium—coronary artery disease	0.000599	0.0191	CbGeAlD
Gefitinib—CHEK2—Pitavastatin—Atorvastatin—coronary artery disease	0.000595	0.262	CbGdCrCtD
Gefitinib—MKNK1—cardiac atrium—coronary artery disease	0.000592	0.0188	CbGeAlD
Gefitinib—CSNK1E—blood—coronary artery disease	0.00057	0.0181	CbGeAlD
Gefitinib—STK10—heart—coronary artery disease	0.00057	0.0181	CbGeAlD
Gefitinib—IRAK4—blood—coronary artery disease	0.000561	0.0178	CbGeAlD
Gefitinib—STK10—cardiovascular system—coronary artery disease	0.000537	0.0171	CbGeAlD
Gefitinib—MKNK2—blood—coronary artery disease	0.000523	0.0166	CbGeAlD
Gefitinib—IRAK1—blood—coronary artery disease	0.000523	0.0166	CbGeAlD
Gefitinib—MKNK1—blood—coronary artery disease	0.000516	0.0164	CbGeAlD
Gefitinib—MAP2K5—heart—coronary artery disease	0.000509	0.0162	CbGeAlD
Gefitinib—MAP2K5—cardiovascular system—coronary artery disease	0.00048	0.0153	CbGeAlD
Gefitinib—MAP2K5—cardiac atrium—coronary artery disease	0.000435	0.0138	CbGeAlD
Gefitinib—STK10—blood—coronary artery disease	0.000425	0.0135	CbGeAlD
Gefitinib—MAP2K5—blood—coronary artery disease	0.00038	0.0121	CbGeAlD
Gefitinib—ALB—heart—coronary artery disease	0.000362	0.0115	CbGeAlD
Gefitinib—CYP1A1—cardiac ventricle—coronary artery disease	0.000358	0.0114	CbGeAlD
Gefitinib—Vandetanib—TEK—coronary artery disease	0.000355	0.0707	CrCbGaD
Gefitinib—Bosutinib—RPS6KB1—coronary artery disease	0.000332	0.0662	CrCbGaD
Gefitinib—ORM1—blood—coronary artery disease	0.000308	0.00981	CbGeAlD
Gefitinib—CHEK2—Testosterone Propionate—Eplerenone—coronary artery disease	0.000285	0.125	CbGdCrCtD
Gefitinib—ABCG2—heart—coronary artery disease	0.000247	0.00788	CbGeAlD
Gefitinib—CYP1A1—heart—coronary artery disease	0.000235	0.00748	CbGeAlD
Gefitinib—CYP2C9—heart—coronary artery disease	0.000226	0.00719	CbGeAlD
Gefitinib—CYP2C19—blood—coronary artery disease	0.000218	0.00692	CbGeAlD
Gefitinib—Lapatinib—CYP2C19—coronary artery disease	0.000216	0.043	CrCbGaD
Gefitinib—CYP2C9—cardiovascular system—coronary artery disease	0.000213	0.00679	CbGeAlD
Gefitinib—CYP1A1—cardiac atrium—coronary artery disease	0.000201	0.00639	CbGeAlD
Gefitinib—ABCG2—blood—coronary artery disease	0.000185	0.00588	CbGeAlD
Gefitinib—CYP1A1—blood—coronary artery disease	0.000175	0.00558	CbGeAlD
Gefitinib—Vandetanib—KDR—coronary artery disease	0.000173	0.0345	CrCbGaD
Gefitinib—CYP3A5—blood—coronary artery disease	0.000171	0.00546	CbGeAlD
Gefitinib—CYP2C9—blood—coronary artery disease	0.000169	0.00537	CbGeAlD
Gefitinib—Iloperidone—HTR7—coronary artery disease	0.000152	0.0302	CrCbGaD
Gefitinib—Vandetanib—VEGFA—coronary artery disease	0.000147	0.0293	CrCbGaD
Gefitinib—CYP3A4—blood—coronary artery disease	0.000129	0.00409	CbGeAlD
Gefitinib—CYP2D6—blood—coronary artery disease	0.000127	0.00403	CbGeAlD
Gefitinib—ABCB1—heart—coronary artery disease	0.000122	0.00388	CbGeAlD
Gefitinib—ABCB1—cardiovascular system—coronary artery disease	0.000115	0.00366	CbGeAlD
Gefitinib—Minaprine—HTR2A—coronary artery disease	0.000104	0.0208	CrCbGaD
Gefitinib—Cisapride—CYP2C19—coronary artery disease	0.000102	0.0203	CrCbGaD
Gefitinib—ABCB1—blood—coronary artery disease	9.1e-05	0.0029	CbGeAlD
Gefitinib—Cisapride—HTR2A—coronary artery disease	8.25e-05	0.0165	CrCbGaD
Gefitinib—Pruritus—Eplerenone—coronary artery disease	7.62e-05	0.000516	CcSEcCtD
Gefitinib—Dyspnoea—Perindopril—coronary artery disease	7.62e-05	0.000516	CcSEcCtD
Gefitinib—Abdominal pain—Niacin—coronary artery disease	7.62e-05	0.000515	CcSEcCtD
Gefitinib—Body temperature increased—Niacin—coronary artery disease	7.62e-05	0.000515	CcSEcCtD
Gefitinib—Iloperidone—HTR2A—coronary artery disease	7.62e-05	0.0152	CrCbGaD
Gefitinib—Malaise—Ramipril—coronary artery disease	7.6e-05	0.000514	CcSEcCtD
Gefitinib—Fatigue—Captopril—coronary artery disease	7.59e-05	0.000513	CcSEcCtD
Gefitinib—Urticaria—Pravastatin—coronary artery disease	7.54e-05	0.00051	CcSEcCtD
Gefitinib—Gastrointestinal pain—Trandolapril—coronary artery disease	7.54e-05	0.00051	CcSEcCtD
Gefitinib—Asthenia—Simvastatin—coronary artery disease	7.53e-05	0.000509	CcSEcCtD
Gefitinib—Diarrhoea—Ezetimibe—coronary artery disease	7.53e-05	0.000509	CcSEcCtD
Gefitinib—Constipation—Captopril—coronary artery disease	7.53e-05	0.000509	CcSEcCtD
Gefitinib—Angioedema—Timolol—coronary artery disease	7.53e-05	0.000509	CcSEcCtD
Gefitinib—Gastrointestinal pain—Enalapril—coronary artery disease	7.51e-05	0.000508	CcSEcCtD
Gefitinib—Abdominal pain—Pravastatin—coronary artery disease	7.5e-05	0.000508	CcSEcCtD
Gefitinib—Body temperature increased—Pravastatin—coronary artery disease	7.5e-05	0.000508	CcSEcCtD
Gefitinib—Hypotension—Losartan—coronary artery disease	7.49e-05	0.000507	CcSEcCtD
Gefitinib—Decreased appetite—Perindopril—coronary artery disease	7.43e-05	0.000503	CcSEcCtD
Gefitinib—Pruritus—Simvastatin—coronary artery disease	7.43e-05	0.000502	CcSEcCtD
Gefitinib—Gastrointestinal pain—Telmisartan—coronary artery disease	7.4e-05	0.000501	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Perindopril—coronary artery disease	7.38e-05	0.000499	CcSEcCtD
Gefitinib—Diarrhoea—Eplerenone—coronary artery disease	7.37e-05	0.000499	CcSEcCtD
Gefitinib—Fatigue—Perindopril—coronary artery disease	7.37e-05	0.000499	CcSEcCtD
Gefitinib—Cough—Ramipril—coronary artery disease	7.35e-05	0.000497	CcSEcCtD
Gefitinib—Urticaria—Trandolapril—coronary artery disease	7.32e-05	0.000495	CcSEcCtD
Gefitinib—Pain—Perindopril—coronary artery disease	7.31e-05	0.000494	CcSEcCtD
Gefitinib—Constipation—Perindopril—coronary artery disease	7.31e-05	0.000494	CcSEcCtD
Gefitinib—Vomiting—Fenofibrate—coronary artery disease	7.31e-05	0.000494	CcSEcCtD
Gefitinib—Hypersensitivity—Valsartan—coronary artery disease	7.3e-05	0.000494	CcSEcCtD
Gefitinib—Urticaria—Enalapril—coronary artery disease	7.29e-05	0.000493	CcSEcCtD
Gefitinib—Body temperature increased—Trandolapril—coronary artery disease	7.29e-05	0.000493	CcSEcCtD
Gefitinib—Abdominal pain—Trandolapril—coronary artery disease	7.29e-05	0.000493	CcSEcCtD
Gefitinib—Abdominal pain—Enalapril—coronary artery disease	7.26e-05	0.000491	CcSEcCtD
Gefitinib—Body temperature increased—Enalapril—coronary artery disease	7.26e-05	0.000491	CcSEcCtD
Gefitinib—Rash—Fenofibrate—coronary artery disease	7.25e-05	0.00049	CcSEcCtD
Gefitinib—Dermatitis—Fenofibrate—coronary artery disease	7.24e-05	0.00049	CcSEcCtD
Gefitinib—Decreased appetite—Furosemide—coronary artery disease	7.22e-05	0.000489	CcSEcCtD
Gefitinib—Gastrointestinal pain—Captopril—coronary artery disease	7.2e-05	0.000487	CcSEcCtD
Gefitinib—Urticaria—Telmisartan—coronary artery disease	7.19e-05	0.000487	CcSEcCtD
Gefitinib—Cough—Timolol—coronary artery disease	7.19e-05	0.000486	CcSEcCtD
Gefitinib—Vomiting—Clopidogrel—coronary artery disease	7.18e-05	0.000486	CcSEcCtD
Gefitinib—Diarrhoea—Simvastatin—coronary artery disease	7.18e-05	0.000486	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Furosemide—coronary artery disease	7.17e-05	0.000485	CcSEcCtD
Gefitinib—Fatigue—Furosemide—coronary artery disease	7.16e-05	0.000485	CcSEcCtD
Gefitinib—Abdominal pain—Telmisartan—coronary artery disease	7.16e-05	0.000484	CcSEcCtD
Gefitinib—Body temperature increased—Telmisartan—coronary artery disease	7.16e-05	0.000484	CcSEcCtD
Gefitinib—Dyspnoea—Losartan—coronary artery disease	7.15e-05	0.000484	CcSEcCtD
Gefitinib—Vomiting—Lovastatin—coronary artery disease	7.14e-05	0.000483	CcSEcCtD
Gefitinib—Rash—Clopidogrel—coronary artery disease	7.12e-05	0.000482	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	7.12e-05	0.000482	CcSEcCtD
Gefitinib—Dermatitis—Clopidogrel—coronary artery disease	7.12e-05	0.000481	CcSEcCtD
Gefitinib—Asthenia—Valsartan—coronary artery disease	7.11e-05	0.000481	CcSEcCtD
Gefitinib—Constipation—Furosemide—coronary artery disease	7.11e-05	0.000481	CcSEcCtD
Gefitinib—Pain—Furosemide—coronary artery disease	7.11e-05	0.000481	CcSEcCtD
Gefitinib—Hypersensitivity—Niacin—coronary artery disease	7.1e-05	0.00048	CcSEcCtD
Gefitinib—Asthenia—Olmesartan—coronary artery disease	7.08e-05	0.000479	CcSEcCtD
Gefitinib—Rash—Lovastatin—coronary artery disease	7.08e-05	0.000479	CcSEcCtD
Gefitinib—Dermatitis—Lovastatin—coronary artery disease	7.07e-05	0.000478	CcSEcCtD
Gefitinib—Anaemia—Lisinopril—coronary artery disease	7.06e-05	0.000478	CcSEcCtD
Gefitinib—Pruritus—Valsartan—coronary artery disease	7.01e-05	0.000474	CcSEcCtD
Gefitinib—Dry mouth—Ramipril—coronary artery disease	7.01e-05	0.000474	CcSEcCtD
Gefitinib—Vomiting—Ezetimibe—coronary artery disease	7e-05	0.000473	CcSEcCtD
Gefitinib—Hypersensitivity—Pravastatin—coronary artery disease	6.99e-05	0.000473	CcSEcCtD
Gefitinib—Gastrointestinal pain—Perindopril—coronary artery disease	6.99e-05	0.000473	CcSEcCtD
Gefitinib—Angioedema—Lisinopril—coronary artery disease	6.98e-05	0.000472	CcSEcCtD
Gefitinib—Pruritus—Olmesartan—coronary artery disease	6.98e-05	0.000472	CcSEcCtD
Gefitinib—Decreased appetite—Losartan—coronary artery disease	6.97e-05	0.000471	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	6.96e-05	0.000471	CcSEcCtD
Gefitinib—Abdominal pain—Captopril—coronary artery disease	6.96e-05	0.000471	CcSEcCtD
Gefitinib—Body temperature increased—Captopril—coronary artery disease	6.96e-05	0.000471	CcSEcCtD
Gefitinib—Rash—Ezetimibe—coronary artery disease	6.94e-05	0.00047	CcSEcCtD
Gefitinib—Dermatitis—Ezetimibe—coronary artery disease	6.93e-05	0.000469	CcSEcCtD
Gefitinib—Asthenia—Niacin—coronary artery disease	6.92e-05	0.000468	CcSEcCtD
Gefitinib—Fatigue—Losartan—coronary artery disease	6.91e-05	0.000468	CcSEcCtD
Gefitinib—Malaise—Lisinopril—coronary artery disease	6.89e-05	0.000466	CcSEcCtD
Gefitinib—Dry mouth—Timolol—coronary artery disease	6.86e-05	0.000464	CcSEcCtD
Gefitinib—Pain—Losartan—coronary artery disease	6.86e-05	0.000464	CcSEcCtD
Gefitinib—Constipation—Losartan—coronary artery disease	6.86e-05	0.000464	CcSEcCtD
Gefitinib—Vomiting—Eplerenone—coronary artery disease	6.85e-05	0.000463	CcSEcCtD
Gefitinib—Nausea—Fenofibrate—coronary artery disease	6.83e-05	0.000462	CcSEcCtD
Gefitinib—Pruritus—Niacin—coronary artery disease	6.82e-05	0.000461	CcSEcCtD
Gefitinib—Asthenia—Pravastatin—coronary artery disease	6.81e-05	0.000461	CcSEcCtD
Gefitinib—Gastrointestinal pain—Furosemide—coronary artery disease	6.8e-05	0.00046	CcSEcCtD
Gefitinib—Rash—Eplerenone—coronary artery disease	6.79e-05	0.00046	CcSEcCtD
Gefitinib—Urticaria—Perindopril—coronary artery disease	6.79e-05	0.000459	CcSEcCtD
Gefitinib—Hypersensitivity—Trandolapril—coronary artery disease	6.79e-05	0.000459	CcSEcCtD
Gefitinib—Dermatitis—Eplerenone—coronary artery disease	6.79e-05	0.000459	CcSEcCtD
Gefitinib—Diarrhoea—Valsartan—coronary artery disease	6.78e-05	0.000459	CcSEcCtD
Gefitinib—Shock—Ramipril—coronary artery disease	6.76e-05	0.000458	CcSEcCtD
Gefitinib—Hypersensitivity—Enalapril—coronary artery disease	6.76e-05	0.000457	CcSEcCtD
Gefitinib—Body temperature increased—Perindopril—coronary artery disease	6.76e-05	0.000457	CcSEcCtD
Gefitinib—Abdominal pain—Perindopril—coronary artery disease	6.76e-05	0.000457	CcSEcCtD
Gefitinib—Diarrhoea—Olmesartan—coronary artery disease	6.75e-05	0.000457	CcSEcCtD
Gefitinib—Nervous system disorder—Ramipril—coronary artery disease	6.74e-05	0.000456	CcSEcCtD
Gefitinib—Thrombocytopenia—Ramipril—coronary artery disease	6.73e-05	0.000455	CcSEcCtD
Gefitinib—Pruritus—Pravastatin—coronary artery disease	6.72e-05	0.000454	CcSEcCtD
Gefitinib—Nausea—Clopidogrel—coronary artery disease	6.71e-05	0.000454	CcSEcCtD
Gefitinib—Skin disorder—Ramipril—coronary artery disease	6.68e-05	0.000452	CcSEcCtD
Gefitinib—Infection—Timolol—coronary artery disease	6.68e-05	0.000452	CcSEcCtD
Gefitinib—Vomiting—Simvastatin—coronary artery disease	6.67e-05	0.000452	CcSEcCtD
Gefitinib—Hypersensitivity—Telmisartan—coronary artery disease	6.67e-05	0.000451	CcSEcCtD
Gefitinib—Cough—Lisinopril—coronary artery disease	6.67e-05	0.000451	CcSEcCtD
Gefitinib—Nausea—Lovastatin—coronary artery disease	6.67e-05	0.000451	CcSEcCtD
Gefitinib—Rash—Simvastatin—coronary artery disease	6.62e-05	0.000448	CcSEcCtD
Gefitinib—Dermatitis—Simvastatin—coronary artery disease	6.61e-05	0.000447	CcSEcCtD
Gefitinib—Asthenia—Trandolapril—coronary artery disease	6.61e-05	0.000447	CcSEcCtD
Gefitinib—Shock—Timolol—coronary artery disease	6.61e-05	0.000447	CcSEcCtD
Gefitinib—Urticaria—Furosemide—coronary artery disease	6.6e-05	0.000447	CcSEcCtD
Gefitinib—Diarrhoea—Niacin—coronary artery disease	6.6e-05	0.000446	CcSEcCtD
Gefitinib—Nervous system disorder—Timolol—coronary artery disease	6.59e-05	0.000446	CcSEcCtD
Gefitinib—Asthenia—Enalapril—coronary artery disease	6.59e-05	0.000446	CcSEcCtD
Gefitinib—Abdominal pain—Furosemide—coronary artery disease	6.57e-05	0.000444	CcSEcCtD
Gefitinib—Body temperature increased—Furosemide—coronary artery disease	6.57e-05	0.000444	CcSEcCtD
Gefitinib—Gastrointestinal pain—Losartan—coronary artery disease	6.56e-05	0.000444	CcSEcCtD
Gefitinib—Anorexia—Ramipril—coronary artery disease	6.55e-05	0.000443	CcSEcCtD
Gefitinib—Nausea—Ezetimibe—coronary artery disease	6.54e-05	0.000442	CcSEcCtD
Gefitinib—Skin disorder—Timolol—coronary artery disease	6.53e-05	0.000442	CcSEcCtD
Gefitinib—Pruritus—Trandolapril—coronary artery disease	6.52e-05	0.000441	CcSEcCtD
Gefitinib—Asthenia—Telmisartan—coronary artery disease	6.5e-05	0.000439	CcSEcCtD
Gefitinib—Pruritus—Enalapril—coronary artery disease	6.49e-05	0.000439	CcSEcCtD
Gefitinib—Diarrhoea—Pravastatin—coronary artery disease	6.49e-05	0.000439	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	6.46e-05	0.000437	CcSEcCtD
Gefitinib—Hypotension—Ramipril—coronary artery disease	6.42e-05	0.000435	CcSEcCtD
Gefitinib—Anorexia—Timolol—coronary artery disease	6.41e-05	0.000433	CcSEcCtD
Gefitinib—Pruritus—Telmisartan—coronary artery disease	6.41e-05	0.000433	CcSEcCtD
Gefitinib—Nausea—Eplerenone—coronary artery disease	6.4e-05	0.000433	CcSEcCtD
Gefitinib—Urticaria—Losartan—coronary artery disease	6.37e-05	0.000431	CcSEcCtD
Gefitinib—Dry mouth—Lisinopril—coronary artery disease	6.36e-05	0.00043	CcSEcCtD
Gefitinib—Abdominal pain—Losartan—coronary artery disease	6.34e-05	0.000429	CcSEcCtD
Gefitinib—Body temperature increased—Losartan—coronary artery disease	6.34e-05	0.000429	CcSEcCtD
Gefitinib—Asthenia—Captopril—coronary artery disease	6.32e-05	0.000427	CcSEcCtD
Gefitinib—Diarrhoea—Trandolapril—coronary artery disease	6.31e-05	0.000427	CcSEcCtD
Gefitinib—Vomiting—Valsartan—coronary artery disease	6.3e-05	0.000426	CcSEcCtD
Gefitinib—Diarrhoea—Enalapril—coronary artery disease	6.28e-05	0.000425	CcSEcCtD
Gefitinib—Hypotension—Timolol—coronary artery disease	6.28e-05	0.000425	CcSEcCtD
Gefitinib—Vomiting—Olmesartan—coronary artery disease	6.27e-05	0.000424	CcSEcCtD
Gefitinib—Rash—Valsartan—coronary artery disease	6.25e-05	0.000423	CcSEcCtD
Gefitinib—Dermatitis—Valsartan—coronary artery disease	6.25e-05	0.000422	CcSEcCtD
Gefitinib—Nausea—Simvastatin—coronary artery disease	6.24e-05	0.000422	CcSEcCtD
Gefitinib—Pruritus—Captopril—coronary artery disease	6.23e-05	0.000421	CcSEcCtD
Gefitinib—Rash—Olmesartan—coronary artery disease	6.22e-05	0.000421	CcSEcCtD
Gefitinib—Dermatitis—Olmesartan—coronary artery disease	6.22e-05	0.00042	CcSEcCtD
Gefitinib—Diarrhoea—Telmisartan—coronary artery disease	6.2e-05	0.000419	CcSEcCtD
Gefitinib—Infection—Lisinopril—coronary artery disease	6.19e-05	0.000419	CcSEcCtD
Gefitinib—Shock—Lisinopril—coronary artery disease	6.13e-05	0.000415	CcSEcCtD
Gefitinib—Asthenia—Perindopril—coronary artery disease	6.13e-05	0.000415	CcSEcCtD
Gefitinib—Dyspnoea—Ramipril—coronary artery disease	6.13e-05	0.000415	CcSEcCtD
Gefitinib—Vomiting—Niacin—coronary artery disease	6.13e-05	0.000415	CcSEcCtD
Gefitinib—Hypersensitivity—Furosemide—coronary artery disease	6.12e-05	0.000414	CcSEcCtD
Gefitinib—Thrombocytopenia—Lisinopril—coronary artery disease	6.1e-05	0.000413	CcSEcCtD
Gefitinib—Rash—Niacin—coronary artery disease	6.08e-05	0.000411	CcSEcCtD
Gefitinib—Dermatitis—Niacin—coronary artery disease	6.07e-05	0.000411	CcSEcCtD
Gefitinib—Skin disorder—Lisinopril—coronary artery disease	6.06e-05	0.00041	CcSEcCtD
Gefitinib—Pruritus—Perindopril—coronary artery disease	6.05e-05	0.000409	CcSEcCtD
Gefitinib—Vomiting—Pravastatin—coronary artery disease	6.03e-05	0.000408	CcSEcCtD
Gefitinib—Diarrhoea—Captopril—coronary artery disease	6.02e-05	0.000407	CcSEcCtD
Gefitinib—Erlotinib—ALB—coronary artery disease	6e-05	0.012	CrCbGaD
Gefitinib—Dyspnoea—Timolol—coronary artery disease	5.99e-05	0.000405	CcSEcCtD
Gefitinib—Rash—Pravastatin—coronary artery disease	5.98e-05	0.000405	CcSEcCtD
Gefitinib—Dermatitis—Pravastatin—coronary artery disease	5.98e-05	0.000404	CcSEcCtD
Gefitinib—Decreased appetite—Ramipril—coronary artery disease	5.98e-05	0.000404	CcSEcCtD
Gefitinib—Asthenia—Furosemide—coronary artery disease	5.96e-05	0.000403	CcSEcCtD
Gefitinib—Anorexia—Lisinopril—coronary artery disease	5.94e-05	0.000402	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ramipril—coronary artery disease	5.94e-05	0.000401	CcSEcCtD
Gefitinib—Fatigue—Ramipril—coronary artery disease	5.93e-05	0.000401	CcSEcCtD
Gefitinib—Hypersensitivity—Losartan—coronary artery disease	5.91e-05	0.0004	CcSEcCtD
Gefitinib—Nausea—Valsartan—coronary artery disease	5.89e-05	0.000398	CcSEcCtD
Gefitinib—Pruritus—Furosemide—coronary artery disease	5.88e-05	0.000398	CcSEcCtD
Gefitinib—Constipation—Ramipril—coronary artery disease	5.88e-05	0.000398	CcSEcCtD
Gefitinib—Nausea—Olmesartan—coronary artery disease	5.86e-05	0.000396	CcSEcCtD
Gefitinib—Vomiting—Trandolapril—coronary artery disease	5.86e-05	0.000396	CcSEcCtD
Gefitinib—Diarrhoea—Perindopril—coronary artery disease	5.85e-05	0.000396	CcSEcCtD
Gefitinib—Decreased appetite—Timolol—coronary artery disease	5.84e-05	0.000395	CcSEcCtD
Gefitinib—Vomiting—Enalapril—coronary artery disease	5.84e-05	0.000395	CcSEcCtD
Gefitinib—Hypotension—Lisinopril—coronary artery disease	5.83e-05	0.000394	CcSEcCtD
Gefitinib—Rash—Trandolapril—coronary artery disease	5.81e-05	0.000393	CcSEcCtD
Gefitinib—Dermatitis—Trandolapril—coronary artery disease	5.81e-05	0.000393	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Timolol—coronary artery disease	5.8e-05	0.000393	CcSEcCtD
Gefitinib—Fatigue—Timolol—coronary artery disease	5.79e-05	0.000392	CcSEcCtD
Gefitinib—Rash—Enalapril—coronary artery disease	5.79e-05	0.000392	CcSEcCtD
Gefitinib—Dermatitis—Enalapril—coronary artery disease	5.78e-05	0.000391	CcSEcCtD
Gefitinib—Vomiting—Telmisartan—coronary artery disease	5.76e-05	0.000389	CcSEcCtD
Gefitinib—Asthenia—Losartan—coronary artery disease	5.75e-05	0.000389	CcSEcCtD
Gefitinib—Pain—Timolol—coronary artery disease	5.75e-05	0.000389	CcSEcCtD
Gefitinib—Nausea—Niacin—coronary artery disease	5.73e-05	0.000387	CcSEcCtD
Gefitinib—Rash—Telmisartan—coronary artery disease	5.71e-05	0.000386	CcSEcCtD
Gefitinib—Dermatitis—Telmisartan—coronary artery disease	5.7e-05	0.000386	CcSEcCtD
Gefitinib—Diarrhoea—Furosemide—coronary artery disease	5.69e-05	0.000385	CcSEcCtD
Gefitinib—Pruritus—Losartan—coronary artery disease	5.67e-05	0.000384	CcSEcCtD
Gefitinib—Nausea—Pravastatin—coronary artery disease	5.64e-05	0.000381	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ramipril—coronary artery disease	5.62e-05	0.00038	CcSEcCtD
Gefitinib—Vomiting—Captopril—coronary artery disease	5.6e-05	0.000379	CcSEcCtD
Gefitinib—Dyspnoea—Lisinopril—coronary artery disease	5.56e-05	0.000376	CcSEcCtD
Gefitinib—Rash—Captopril—coronary artery disease	5.55e-05	0.000376	CcSEcCtD
Gefitinib—Dermatitis—Captopril—coronary artery disease	5.55e-05	0.000375	CcSEcCtD
Gefitinib—Gastrointestinal pain—Timolol—coronary artery disease	5.5e-05	0.000372	CcSEcCtD
Gefitinib—Diarrhoea—Losartan—coronary artery disease	5.49e-05	0.000371	CcSEcCtD
Gefitinib—Nausea—Trandolapril—coronary artery disease	5.47e-05	0.00037	CcSEcCtD
Gefitinib—Urticaria—Ramipril—coronary artery disease	5.46e-05	0.000369	CcSEcCtD
Gefitinib—Nausea—Enalapril—coronary artery disease	5.45e-05	0.000369	CcSEcCtD
Gefitinib—Vomiting—Perindopril—coronary artery disease	5.44e-05	0.000368	CcSEcCtD
Gefitinib—Abdominal pain—Ramipril—coronary artery disease	5.44e-05	0.000368	CcSEcCtD
Gefitinib—Body temperature increased—Ramipril—coronary artery disease	5.44e-05	0.000368	CcSEcCtD
Gefitinib—Decreased appetite—Lisinopril—coronary artery disease	5.42e-05	0.000367	CcSEcCtD
Gefitinib—Rash—Perindopril—coronary artery disease	5.39e-05	0.000365	CcSEcCtD
Gefitinib—Dermatitis—Perindopril—coronary artery disease	5.38e-05	0.000364	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Lisinopril—coronary artery disease	5.38e-05	0.000364	CcSEcCtD
Gefitinib—Nausea—Telmisartan—coronary artery disease	5.38e-05	0.000364	CcSEcCtD
Gefitinib—Fatigue—Lisinopril—coronary artery disease	5.38e-05	0.000364	CcSEcCtD
Gefitinib—Urticaria—Timolol—coronary artery disease	5.34e-05	0.000361	CcSEcCtD
Gefitinib—Constipation—Lisinopril—coronary artery disease	5.33e-05	0.000361	CcSEcCtD
Gefitinib—Pain—Lisinopril—coronary artery disease	5.33e-05	0.000361	CcSEcCtD
Gefitinib—Abdominal pain—Timolol—coronary artery disease	5.31e-05	0.000359	CcSEcCtD
Gefitinib—Body temperature increased—Timolol—coronary artery disease	5.31e-05	0.000359	CcSEcCtD
Gefitinib—Vomiting—Furosemide—coronary artery disease	5.28e-05	0.000357	CcSEcCtD
Gefitinib—Rash—Furosemide—coronary artery disease	5.24e-05	0.000354	CcSEcCtD
Gefitinib—Dermatitis—Furosemide—coronary artery disease	5.23e-05	0.000354	CcSEcCtD
Gefitinib—Nausea—Captopril—coronary artery disease	5.23e-05	0.000354	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lisinopril—coronary artery disease	5.1e-05	0.000345	CcSEcCtD
Gefitinib—Vomiting—Losartan—coronary artery disease	5.1e-05	0.000345	CcSEcCtD
Gefitinib—Nausea—Perindopril—coronary artery disease	5.08e-05	0.000343	CcSEcCtD
Gefitinib—Hypersensitivity—Ramipril—coronary artery disease	5.07e-05	0.000343	CcSEcCtD
Gefitinib—Rash—Losartan—coronary artery disease	5.06e-05	0.000342	CcSEcCtD
Gefitinib—Dermatitis—Losartan—coronary artery disease	5.05e-05	0.000342	CcSEcCtD
Gefitinib—Urticaria—Lisinopril—coronary artery disease	4.95e-05	0.000335	CcSEcCtD
Gefitinib—Hypersensitivity—Timolol—coronary artery disease	4.95e-05	0.000335	CcSEcCtD
Gefitinib—Nausea—Furosemide—coronary artery disease	4.94e-05	0.000334	CcSEcCtD
Gefitinib—Asthenia—Ramipril—coronary artery disease	4.93e-05	0.000334	CcSEcCtD
Gefitinib—Abdominal pain—Lisinopril—coronary artery disease	4.93e-05	0.000333	CcSEcCtD
Gefitinib—Body temperature increased—Lisinopril—coronary artery disease	4.93e-05	0.000333	CcSEcCtD
Gefitinib—Pruritus—Ramipril—coronary artery disease	4.86e-05	0.000329	CcSEcCtD
Gefitinib—Asthenia—Timolol—coronary artery disease	4.82e-05	0.000326	CcSEcCtD
Gefitinib—Nausea—Losartan—coronary artery disease	4.76e-05	0.000322	CcSEcCtD
Gefitinib—Pruritus—Timolol—coronary artery disease	4.76e-05	0.000322	CcSEcCtD
Gefitinib—Diarrhoea—Ramipril—coronary artery disease	4.7e-05	0.000318	CcSEcCtD
Gefitinib—Diarrhoea—Timolol—coronary artery disease	4.6e-05	0.000311	CcSEcCtD
Gefitinib—Hypersensitivity—Lisinopril—coronary artery disease	4.59e-05	0.000311	CcSEcCtD
Gefitinib—Asthenia—Lisinopril—coronary artery disease	4.47e-05	0.000303	CcSEcCtD
Gefitinib—Pruritus—Lisinopril—coronary artery disease	4.41e-05	0.000298	CcSEcCtD
Gefitinib—Vomiting—Ramipril—coronary artery disease	4.37e-05	0.000296	CcSEcCtD
Gefitinib—Rash—Ramipril—coronary artery disease	4.33e-05	0.000293	CcSEcCtD
Gefitinib—Dermatitis—Ramipril—coronary artery disease	4.33e-05	0.000293	CcSEcCtD
Gefitinib—Vomiting—Timolol—coronary artery disease	4.27e-05	0.000289	CcSEcCtD
Gefitinib—Diarrhoea—Lisinopril—coronary artery disease	4.27e-05	0.000289	CcSEcCtD
Gefitinib—Rash—Timolol—coronary artery disease	4.24e-05	0.000287	CcSEcCtD
Gefitinib—Dermatitis—Timolol—coronary artery disease	4.23e-05	0.000286	CcSEcCtD
Gefitinib—Nausea—Ramipril—coronary artery disease	4.08e-05	0.000276	CcSEcCtD
Gefitinib—Nausea—Timolol—coronary artery disease	3.99e-05	0.00027	CcSEcCtD
Gefitinib—Vomiting—Lisinopril—coronary artery disease	3.96e-05	0.000268	CcSEcCtD
Gefitinib—Vandetanib—ALB—coronary artery disease	3.95e-05	0.00787	CrCbGaD
Gefitinib—Rash—Lisinopril—coronary artery disease	3.93e-05	0.000266	CcSEcCtD
Gefitinib—Dermatitis—Lisinopril—coronary artery disease	3.93e-05	0.000266	CcSEcCtD
Gefitinib—Nausea—Lisinopril—coronary artery disease	3.7e-05	0.000251	CcSEcCtD
Gefitinib—ABCB1—Metabolism—GGT1—coronary artery disease	1.32e-06	9.61e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GOT1—coronary artery disease	1.32e-06	9.61e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAT—coronary artery disease	1.31e-06	9.58e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLCB3—coronary artery disease	1.31e-06	9.58e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLCB1—coronary artery disease	1.31e-06	9.56e-06	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—coronary artery disease	1.31e-06	9.55e-06	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—coronary artery disease	1.3e-06	9.51e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—coronary artery disease	1.3e-06	9.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—coronary artery disease	1.3e-06	9.49e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA5—coronary artery disease	1.3e-06	9.48e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—coronary artery disease	1.3e-06	9.45e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—coronary artery disease	1.29e-06	9.43e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.29e-06	9.38e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GSK3B—coronary artery disease	1.28e-06	9.36e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCA1—coronary artery disease	1.28e-06	9.35e-06	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—coronary artery disease	1.28e-06	9.33e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOB—coronary artery disease	1.27e-06	9.3e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—P4HB—coronary artery disease	1.27e-06	9.3e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—coronary artery disease	1.27e-06	9.29e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—POMC—coronary artery disease	1.27e-06	9.29e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREB1—coronary artery disease	1.27e-06	9.29e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCA1—coronary artery disease	1.27e-06	9.27e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CD36—coronary artery disease	1.27e-06	9.26e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPP2CA—coronary artery disease	1.25e-06	9.14e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	1.25e-06	9.13e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—coronary artery disease	1.25e-06	9.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—coronary artery disease	1.24e-06	9.09e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6R—coronary artery disease	1.24e-06	9.06e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GOT1—coronary artery disease	1.24e-06	9.05e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GGT1—coronary artery disease	1.24e-06	9.05e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—coronary artery disease	1.24e-06	9.05e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—coronary artery disease	1.24e-06	9.04e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GGT1—coronary artery disease	1.23e-06	8.97e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GOT1—coronary artery disease	1.23e-06	8.97e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—coronary artery disease	1.22e-06	8.93e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—coronary artery disease	1.22e-06	8.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—coronary artery disease	1.22e-06	8.89e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—LPL—coronary artery disease	1.22e-06	8.88e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—coronary artery disease	1.21e-06	8.84e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGT—coronary artery disease	1.21e-06	8.82e-06	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—coronary artery disease	1.2e-06	8.78e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—coronary artery disease	1.2e-06	8.77e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARGC1A—coronary artery disease	1.2e-06	8.76e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—coronary artery disease	1.2e-06	8.72e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—coronary artery disease	1.19e-06	8.72e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—coronary artery disease	1.19e-06	8.67e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—coronary artery disease	1.18e-06	8.65e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—coronary artery disease	1.18e-06	8.63e-06	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—coronary artery disease	1.18e-06	8.61e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—VCAN—coronary artery disease	1.18e-06	8.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAT—coronary artery disease	1.18e-06	8.6e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARGC1A—coronary artery disease	1.17e-06	8.55e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOA1—coronary artery disease	1.17e-06	8.55e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOA—coronary artery disease	1.17e-06	8.54e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—coronary artery disease	1.17e-06	8.51e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—coronary artery disease	1.16e-06	8.49e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—coronary artery disease	1.16e-06	8.48e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CD36—coronary artery disease	1.16e-06	8.44e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAT—coronary artery disease	1.15e-06	8.4e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOB—coronary artery disease	1.14e-06	8.35e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGT—coronary artery disease	1.14e-06	8.34e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPP2CA—coronary artery disease	1.14e-06	8.34e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DCN—coronary artery disease	1.14e-06	8.29e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—coronary artery disease	1.13e-06	8.27e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF2—coronary artery disease	1.13e-06	8.21e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—coronary artery disease	1.12e-06	8.18e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—coronary artery disease	1.12e-06	8.17e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOB—coronary artery disease	1.12e-06	8.15e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—coronary artery disease	1.11e-06	8.13e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—coronary artery disease	1.11e-06	8.12e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—coronary artery disease	1.11e-06	8.12e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—coronary artery disease	1.11e-06	8.1e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOA1—coronary artery disease	1.11e-06	8.08e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDH2—coronary artery disease	1.11e-06	8.06e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—coronary artery disease	1.1e-06	8.06e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	1.1e-06	8.06e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—coronary artery disease	1.1e-06	8.02e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—coronary artery disease	1.1e-06	8.01e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—coronary artery disease	1.1e-06	8e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	1.09e-06	7.99e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—LPL—coronary artery disease	1.09e-06	7.98e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—coronary artery disease	1.09e-06	7.95e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—coronary artery disease	1.09e-06	7.93e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAT—coronary artery disease	1.08e-06	7.91e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JAK2—coronary artery disease	1.08e-06	7.87e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LIPC—coronary artery disease	1.08e-06	7.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HBA1—coronary artery disease	1.08e-06	7.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	1.08e-06	7.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	1.08e-06	7.86e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—coronary artery disease	1.08e-06	7.85e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAT—coronary artery disease	1.07e-06	7.84e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOC3—coronary artery disease	1.07e-06	7.81e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—LPL—coronary artery disease	1.07e-06	7.78e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—coronary artery disease	1.07e-06	7.78e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LDLR—coronary artery disease	1.06e-06	7.76e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—coronary artery disease	1.06e-06	7.74e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.06e-06	7.73e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—coronary artery disease	1.06e-06	7.71e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOB—coronary artery disease	1.05e-06	7.68e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	1.05e-06	7.67e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—coronary artery disease	1.05e-06	7.67e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—coronary artery disease	1.05e-06	7.65e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOB—coronary artery disease	1.04e-06	7.62e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGT—coronary artery disease	1.04e-06	7.6e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—coronary artery disease	1.04e-06	7.59e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CETP—coronary artery disease	1.04e-06	7.58e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCLC—coronary artery disease	1.04e-06	7.58e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD36—coronary artery disease	1.04e-06	7.58e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—coronary artery disease	1.03e-06	7.53e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—coronary artery disease	1.03e-06	7.52e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—coronary artery disease	1.03e-06	7.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SDC1—coronary artery disease	1.03e-06	7.5e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPP2CA—coronary artery disease	1.03e-06	7.48e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—coronary artery disease	1.02e-06	7.47e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—coronary artery disease	1.02e-06	7.45e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—coronary artery disease	1.02e-06	7.43e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—coronary artery disease	1.02e-06	7.41e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD36—coronary artery disease	1.01e-06	7.4e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOA1—coronary artery disease	1.01e-06	7.36e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—LPL—coronary artery disease	1.01e-06	7.34e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPP2CA—coronary artery disease	1e-06	7.3e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—LPL—coronary artery disease	9.96e-07	7.27e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—coronary artery disease	9.93e-07	7.25e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—coronary artery disease	9.84e-07	7.18e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—coronary artery disease	9.84e-07	7.18e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—coronary artery disease	9.81e-07	7.16e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—coronary artery disease	9.75e-07	7.12e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—coronary artery disease	9.72e-07	7.09e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSMA6—coronary artery disease	9.71e-07	7.08e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSMB5—coronary artery disease	9.71e-07	7.08e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	9.66e-07	7.05e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—coronary artery disease	9.66e-07	7.05e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—coronary artery disease	9.62e-07	7.02e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—coronary artery disease	9.6e-07	7.01e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD36—coronary artery disease	9.55e-07	6.97e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—coronary artery disease	9.51e-07	6.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CTGF—coronary artery disease	9.48e-07	6.92e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD36—coronary artery disease	9.47e-07	6.91e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	9.43e-07	6.88e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—coronary artery disease	9.42e-07	6.88e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMGCR—coronary artery disease	9.4e-07	6.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GOT2—coronary artery disease	9.4e-07	6.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—coronary artery disease	9.36e-07	6.83e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPP2CA—coronary artery disease	9.35e-07	6.82e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGT—coronary artery disease	9.35e-07	6.82e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—coronary artery disease	9.34e-07	6.81e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—coronary artery disease	9.28e-07	6.77e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—coronary artery disease	9.17e-07	6.69e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—coronary artery disease	9.16e-07	6.69e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—coronary artery disease	9.16e-07	6.68e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGT—coronary artery disease	9.13e-07	6.66e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOA1—coronary artery disease	9.06e-07	6.61e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—coronary artery disease	9.05e-07	6.6e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—coronary artery disease	8.97e-07	6.55e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—coronary artery disease	8.94e-07	6.52e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—coronary artery disease	8.92e-07	6.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—coronary artery disease	8.9e-07	6.5e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—coronary artery disease	8.89e-07	6.49e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—coronary artery disease	8.88e-07	6.48e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOA1—coronary artery disease	8.84e-07	6.45e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—coronary artery disease	8.77e-07	6.4e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—coronary artery disease	8.77e-07	6.4e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	8.67e-07	6.33e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—coronary artery disease	8.67e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLCB1—coronary artery disease	8.64e-07	6.31e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—coronary artery disease	8.63e-07	6.3e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGT—coronary artery disease	8.6e-07	6.28e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—coronary artery disease	8.55e-07	6.24e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGT—coronary artery disease	8.52e-07	6.22e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—coronary artery disease	8.43e-07	6.15e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—coronary artery disease	8.39e-07	6.12e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCA1—coronary artery disease	8.37e-07	6.11e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—coronary artery disease	8.35e-07	6.1e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOA1—coronary artery disease	8.33e-07	6.08e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—coronary artery disease	8.27e-07	6.03e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOA1—coronary artery disease	8.26e-07	6.03e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—coronary artery disease	8.12e-07	5.92e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GGT1—coronary artery disease	8.11e-07	5.92e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GOT1—coronary artery disease	8.11e-07	5.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—coronary artery disease	7.99e-07	5.83e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—coronary artery disease	7.98e-07	5.82e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	7.91e-07	5.77e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—coronary artery disease	7.9e-07	5.76e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—coronary artery disease	7.89e-07	5.76e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—coronary artery disease	7.87e-07	5.74e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—coronary artery disease	7.79e-07	5.68e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—coronary artery disease	7.68e-07	5.61e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—coronary artery disease	7.67e-07	5.6e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—coronary artery disease	7.64e-07	5.58e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—coronary artery disease	7.63e-07	5.57e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—coronary artery disease	7.34e-07	5.36e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—coronary artery disease	7.34e-07	5.35e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—coronary artery disease	7.29e-07	5.32e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—coronary artery disease	7.28e-07	5.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—coronary artery disease	7.28e-07	5.31e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—coronary artery disease	7.24e-07	5.28e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	7.22e-07	5.27e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—coronary artery disease	7.2e-07	5.25e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—coronary artery disease	7.19e-07	5.24e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—coronary artery disease	7.18e-07	5.24e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—coronary artery disease	7.17e-07	5.24e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAT—coronary artery disease	7.09e-07	5.17e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—coronary artery disease	7e-07	5.11e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—coronary artery disease	6.99e-07	5.1e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—coronary artery disease	6.97e-07	5.09e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOB—coronary artery disease	6.88e-07	5.02e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—coronary artery disease	6.86e-07	5.01e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—coronary artery disease	6.7e-07	4.89e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—coronary artery disease	6.7e-07	4.89e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—coronary artery disease	6.6e-07	4.82e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LPL—coronary artery disease	6.57e-07	4.8e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—coronary artery disease	6.54e-07	4.77e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—coronary artery disease	6.41e-07	4.68e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—coronary artery disease	6.31e-07	4.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—coronary artery disease	6.28e-07	4.58e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—coronary artery disease	6.26e-07	4.57e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD36—coronary artery disease	6.24e-07	4.56e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—coronary artery disease	6.24e-07	4.56e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	6.17e-07	4.5e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—coronary artery disease	6.13e-07	4.47e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—coronary artery disease	5.92e-07	4.32e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—coronary artery disease	5.77e-07	4.21e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—coronary artery disease	5.72e-07	4.18e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—coronary artery disease	5.69e-07	4.16e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGT—coronary artery disease	5.62e-07	4.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—coronary artery disease	5.53e-07	4.03e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—coronary artery disease	5.51e-07	4.02e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA1—coronary artery disease	5.45e-07	3.97e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—coronary artery disease	5.1e-07	3.72e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—coronary artery disease	4.99e-07	3.65e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—coronary artery disease	4.8e-07	3.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—coronary artery disease	4.73e-07	3.45e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—coronary artery disease	4.72e-07	3.44e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—coronary artery disease	4.31e-07	3.15e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—coronary artery disease	4.3e-07	3.14e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—coronary artery disease	4.13e-07	3.01e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—coronary artery disease	4.08e-07	2.98e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—coronary artery disease	3.86e-07	2.82e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—coronary artery disease	3.85e-07	2.81e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—coronary artery disease	3.77e-07	2.75e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—coronary artery disease	3.77e-07	2.75e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	3.55e-07	2.59e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—coronary artery disease	3.52e-07	2.57e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—coronary artery disease	3.51e-07	2.56e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—coronary artery disease	3.15e-07	2.3e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—coronary artery disease	3.08e-07	2.25e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—coronary artery disease	2.9e-07	2.12e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—coronary artery disease	2.88e-07	2.1e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	2.32e-07	1.69e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—coronary artery disease	1.9e-07	1.38e-06	CbGpPWpGaD
